Renske Mt Ten Ham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3659176/publications.pdf

Version: 2024-02-01

1478505 1199594 12 305 12 6 citations h-index g-index papers 13 13 13 470 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A. HemaSphere, 2022, 6, e679.	2.7	7
2	Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. Value in Health, 2022, 25, 390-399.	0.3	8
3	Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. Value in Health, 2021, 24, 121-128.	0.3	6
4	Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy, 2021, 23, 730-739.	0.7	12
5	Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. Clinical Genitourinary Cancer, 2020, 18, e21-e27.	1.9	4
6	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 2020, 22, 388-397.	0.7	29
7	A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature. Value in Health, 2020, 23, 1268-1280.	0.3	14
8	Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection. Trends in Pharmacological Sciences, 2020, 41, 67-71.	8.7	5
9	Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. European Urology, 2019, 76, 743-751.	1.9	5
10	Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. Molecular Therapy - Methods and Clinical Development, 2018, 11, 121-130.	4.1	63
11	Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology. JMIR Cancer, 2018, 4, e11.	2.4	15
12	Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. Value in Health, 2017, 20, 520-532.	0.3	137